TOWARDS THE end of May, Russia shipped nearly a quarter of a million packs of medicines to India as humanitarian assistance to fight the devastating second wave of the covid-19 pandemic. The packs contained the Russian generic version of Gilead’s experimental anti-viral drug remdesivir that is used to treat patients hospitalised with the deadly infection. The arrival of Remdeform, as the drug is called, highlighted the timidity of New Delhi in using its robust laws to make lifesaving drugs accessible and inexpensive.
Remdeform is being manufactured in Russia using a compulsory licence (CL) which is a flexibility permitted under the World Trade Organization’s (WTO) strict intellectual property (IP) rules. These rules, labelled trips or the trade-related aspects of IP rights, allow member-countries to override the rights of the patent holders in the case of a national emergency on health. In India, remdesivir is manufactured through voluntary licences (VLs) granted by Gilead, the patent holder, to generic-drug manufacturers that are allowed to make and export the drug according to the terms laid down by the originator company. Eight companies hold such licences.
VLs are considered less messy because they are quick and avoid the legal challenges that a CL invariably results in, although these are issued in special circumstances. VLs usually allow the firms to set their own prices even if the export markets are strictly circumscribed. Yet, remdesivir production by the Indian companies was not enough to meet the crisis in April-May as both demand and prices spiralled out of control, forcing India to seek assistance.
This story is from the June 16, 2021 edition of Down To Earth.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the June 16, 2021 edition of Down To Earth.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
In leading role again
MOVIES AND WEB SERIES ARE ONCE AGAIN BEING SET IN RUSTIC BACKGROUNDS, INDICATING A RECONNECT BETWEEN CINEMA AND THE COUNTRYSIDE
One Nation One Subscription comes at a huge cost
As top US universities scrap big deals with top scientific publishers, India’s ONOS scheme seems flawed and outdated
Return of Rambhog
Bid to revive and sell the aromatic indigenous paddy variety has led to substantial profits for farmers in Uttar Pradesh's Terai region
Scarred by mining
Natural springs of Kashmir drying up due to illegal riverbed mining
Human-to-human spread a mutation away
CANADA IN mid-November confirmed its first human case of avian influenza, with a teenager in the British Columbia being hospitalised after contracting the H5N1 virus that causes the disease. The patient developed a severe form of the disease, also called bird flu, and had respiratory issues. There was no known cause of transmission.
True rehabilitation
Residents of Madhya Pradesh's Kakdi village take relocation as an opportunity to undertake afforestation, develop sustainable practices
INESCAPABLE THREAT
Chemical pollution is the most underrated and underreported risk of the 21st century that threatens all species and regions
THAT NIGHT, 40 YEARS AGO
Bhopal gas disaster is a tragedy that people continue to face
A JOKE, INDEED
A CONFERENCE OF IRRESPONSIBLE PARTIES THAT CREATED AN OPTICAL ILLUSION TO THE REALITY OF A NEW CLIMATE
THINGS FALL APART
THE WORLD HAS MADE PROGRESS IN MITIGATING EMISSIONS AND ADAPTING TO CLIMATE IMPACTS. BUT THE PROGRESS REMAINS GROSSLY INADEQUATE
